Desıgn Optımızatıon and Evaluatıon of Mesoporous Sılıca Based Lıquısolıd Blends of Azelnıdıpıne

Abstract

Azelnidipine is a calcium channel inhibitor widely utilized for the management of hypertension. The therapeutic benefits are restricted due to high lipophilicity. The recent work focused on the enhancement of solubility dissolution rate and bioavailability of Azelnidipine by the Liquisolid Compact technique. One of the best solubility enhancement techniques for BCS-II potent molecules is the Liquisolid Compaq technique. The hydrophobic active ingredient is converted into the liquid medicament by adding a non-volatile solvent. Furthermore, the freely flowable and compressible powder blends were accomplished by the amalgamation of adsorbents. The highest solubility of Azelnidipine was observed in PEG 400. The drug-excipient interactions were checked with FTIR and DSC. The screening was performed with the Design of expert software with MCC 102 (X1), Parteck SLC (X2), crosspovidone (X3) as independent factors and disintegration (Y1) dissolution release (Y2) as dependable factors with 12 trial runs. The ANOVA was applied with a polynomial quadratic model with response surface methodology. The optimized batch F5 indicated excellent flowability characteristics, the least disintegration time (4.05 min), and the greatest dissolution release (99.31%) owing to the greatest adsorption capacity and surface area of mesoporous silica.